The DOI matches its Crossref record.
Pancreatic Extracts in The Treatment of Diabetes Mellitus
Abstract
Since the year 1889, when von Mering and Minkowski produced severe and fatal diabetes by total removal of the pancreas in dogs, many investigators have endeavoured to obtain some beneficial effect in diabetes mellitus, either by feeding pancreas, or by administration of pancreatic extracts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
A RELATION BETWEEN NON-ESTERIFIED FATTY ACIDS IN PLASMA AND THE METABOLISM OF GLUCOSE
Dole, V. P. (1956) · Journal of Clinical Investigation · doi:10.1172/jci103259 · Cited by 3,454
Therapeutic peptides: Historical perspectives, current development trends, and future directions
Lau, J. L., & Dunn, M. K. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.06.052 · Cited by 1,879
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
“The exogenous supplementation of native hormones, commonly purified from tissue homogenates, has led to numerous, seminal discoveries, most prominently the identification of insulin in 1921 [875] followed by the discovery of glucagon in 1923 [3].”
BackgroundAnimal models of obesity and diabetes mellitus
Kleinert, M., Clemmensen, C., Hofmann, S. M., Moore, M. C., Renner, S., Woods, S. C., Huypens, P., Beckers, J., de Angelis, M. H., Schürmann, A., et al. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.161 · Cited by 832
Biochemical and cellular properties of insulin receptor signalling
Haeusler, R. A., McGraw, T. E., & Accili, D. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.89 · Cited by 739
A Comprehensive Review on Current Advances in Peptide Drug Development and Design
Lee, A. C.-L., Harris, J. L., Khanna, K. K., & Hong, J.-H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102383 · Cited by 686
Stimuli-responsive nanomaterials for therapeutic protein delivery
Lu, Y., Sun, W., & Gu, Z. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.08.015 · Cited by 415
Pasquel, F. J., & Umpierrez, G. E. (2014) · Diabetes Care · doi:10.2337/dc14-0984 · Cited by 345
TLR4 at the Crossroads of Nutrients, Gut Microbiota, and Metabolic Inflammation
Velloso, L. A., Folli, F., & Saad, M. J. (2015) · Endocrine Reviews · doi:10.1210/er.2014-1100 · Cited by 337
Hypomagnesemia in Type 2 Diabetes: A Vicious Circle?
Gommers, L. M. M., Hoenderop, J. G. J., Bindels, R. J. M., & de Baaij, J. H. F. (2016) · Diabetes · doi:10.2337/db15-1028 · Cited by 334
Alzheimer’s disease and insulin resistance: translating basic science into clinical applications
De Felice, F. G. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64595 · Cited by 330
Scharp, D. W., & Marchetti, P. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.07.018 · Cited by 314
Hyperinsulinemia in Obesity, Inflammation, and Cancer
Zhang, A. M. Y., Wellberg, E. A., Kopp, J. L., & Johnson, J. D. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0250 · Cited by 305
Insulin in the Brain: Sources, Localization and Functions
Ghasemi, R., Haeri, A., Dargahi, L., Mohamed, Z., & Ahmadiani, A. (2013) · Molecular Neurobiology · doi:10.1007/s12035-012-8339-9 · Cited by 290
Insulin delivery systems combined with microneedle technology
Jin, X., Zhu, D. D., Chen, B. Z., Ashfaq, M., & Guo, X. D. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.03.011 · Cited by 275
Peptidomimetic therapeutics: scientific approaches and opportunities
Qvit, N., Rubin, S. J. S., Urban, T. J., Mochly-Rosen, D., & Gross, E. R. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2016.11.003 · Cited by 273
100 years of insulin: celebrating the past, present and future of diabetes therapy
Sims, E. K., Carr, A. L. J., Oram, R. A., DiMeglio, L. A., & Evans-Molina, C. (2021) · Nature Medicine · doi:10.1038/s41591-021-01418-2 · Cited by 270
New frontiers in the treatment of type 1 diabetes
Warshauer, J. T., Bluestone, J. A., & Anderson, M. S. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.11.017 · Cited by 259
“Nearly a century ago, the discovery of insulin by Frederick Banting and Charles Best (Banting et al., 1922) turned T1D from an acutely fatal disease into a chronic disease that could be managed with exogenous insulin administration.”
BackgroundRomero, R., Erez, O., Hüttemann, M., Maymon, E., Panaitescu, B., Conde-Agudelo, A., Pacora, P., Yoon, B. H., & Grossman, L. I. (2017) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2017.06.003 · Cited by 253
Anti-obesity therapy: from rainbow pills to polyagonists
Müller, T. D., Clemmensen, C., Finan, B., DiMarchi, R. D., & Tschöp, M. H. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014803 · Cited by 199
Reappraisal of GIP Pharmacology for Metabolic Diseases
Finan, B., Müller, T. D., Clemmensen, C., Perez-Tilve, D., DiMarchi, R. D., & Tschöp, M. H. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.03.005 · Cited by 180
The journey of islet cell transplantation and future development
Gamble, A., Pepper, A. R., Bruni, A., & Shapiro, A. M. J. (2018) · Islets · doi:10.1080/19382014.2018.1428511 · Cited by 171
A causal role for hyperinsulinemia in obesity
Templeman, N. M., Skovsø, S., Page, M. M., Lim, G. E., & Johnson, J. D. (2017) · Journal of Endocrinology · doi:10.1530/joe-16-0449 · Cited by 168
The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes
Hædersdal, S., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.12.003 · Cited by 162
“T he opposing actions of insulin and glucagon were demonstrated nearly a century ago.(1,2) Today, the role of glucagon is recognized as important in glucose homeostasis and diabetes pathophysiology.”
BackgroundHyperinsulinemia: A cause of obesity?
Erion, K. A., & Corkey, B. E. (2017) · Current Obesity Reports · doi:10.1007/s13679-017-0261-z · Cited by 161
Transforming obesity: The advancement of multi-receptor drugs
Kusminski, C. M., Perez-Tilve, D., Müller, T. D., DiMarchi, R. D., Tschöp, M. H., & Scherer, P. E. (2024) · Cell · doi:10.1016/j.cell.2024.06.003 · Cited by 126
Zinc, pancreatic islet cell function and diabetes: new insights into an old story
Chimienti, F. (2013) · Nutrition Research Reviews · doi:10.1017/s0954422412000212 · Cited by 125
“Insulin, the glucose-lowering hormone secreted by pancreatic b -cells, was discovered in 1921 in Toronto by Best and Banting, after they isolated pancreatic extracts without contamination of the tissue extract with digestive enzymes (1) .”
Glucagon secretion from pancreatic α-cells
Briant, L., Salehi, A., Vergari, E., Zhang, Q., & Rorsman, P. (2016) · Upsala Journal of Medical Sciences · doi:10.3109/03009734.2016.1156789 · Cited by 109
“When Banting and Best (1) injected extracts from pancreatic tissue intravenously or subcutaneously into diabetic dogs and humans, they observed a marked reduction in blood sugar (reflecting the hypoglycaemic action of insulin).”
BackgroundThe Future of Islet Transplantation Is Now
Bottino, R., Knoll, M. F., Knoll, C. A., Bertera, S., & Trucco, M. M. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00202 · Cited by 93
“Beginning with the discovery of insulin by Frederick Banting and Charles Best in 1922 (1, 2, 9), for which Banting, but not Best, won a Nobel Prize the following year, diabetes went from being a terminal disease to a chronic one.”
The effects of dual GLP-1/GIP receptor agonism on glucagon secretion-A Review
Mathiesen, D. S., Bagger, J. I., Bergmann, N. C., Lund, A., Christensen, M. B., Vilsbøll, T., & Knop, F. K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174092 · Cited by 80
In situ cell-type-specific cell-surface proteomic profiling in mice
Shuster, S. A., Li, J., Chon, U., Sinantha-Hu, M. C., Luginbuhl, D. J., Udeshi, N. D., Carey, D. K., Takeo, Y. H., Xie, Q., Xu, C., et al. (2022) · Neuron · doi:10.1016/j.neuron.2022.09.025 · Cited by 70
“…of CSPs was biased towards secreted and lipid-anchored proteins due to their relative ease of purification compared to transmembrane proteins (Banting et al., 1922; Brazeau et al., 1973; Cohen et al., 1954; Dinarello et al., 1977; Drescher et al., 1995; Serafini et al., 1994). iPEEL,…”
Little, S. A., Leelarathna, L., Barendse, S. M., Walkinshaw, E., Tan, H. K., Lubina Solomon, A., de Zoysa, N., Rogers, H., Choudhary, P., Amiel, S. A., et al. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2492 · Cited by 48
Main methods and tools for peptide development based on protein-protein interactions (PPIs)
Baeza, J., Bedoya, M., Cruz, P., Ojeda, P., Adasme-Carreño, F., Cerda, O., & González, W. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.151623 · Cited by 8
Adelmeyer, J., Schauer, C. M., & Kann, P. H. (2024) · Hormones · doi:10.1007/s42000-024-00542-1 · Cited by 4
Metadata
- Authors
- Banting, F. G., Best, C. H., Collip, J. B., Campbell, W. R., & Fletcher, A. A.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 1956-01-01
- Volume
- 5
- Issue
- 1
- Pages
- 69-71
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2126640907
- Cited by
- 347
- References
- 0
- FWCI
- 1.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.